Evidence map›Paper›PMID 41509421›Full record

ArticlebioRxiv : the preprint server for biology2025

Aging-induced hepatocyte CD44 drives IL6/STAT3 signaling and associates with impaired neighboring T cell function.

Armin Gandhi, Kathryn Lande, Yichen Li, Filipe A Hoffman, Michael LaPorte, Shirong Tan, Garrett Evensen, Benji Portillo, Marcos Garcia Teneche, Rouven Arnold and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Armin GandhiSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.ORCID 0000-0002-8246-4663
Kathryn LandeSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Yichen LiSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Filipe A HoffmanNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, California, USA.
Michael LaPorteNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, California, USA.
Shirong TanNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, California, USA.
Garrett EvensenSalk Institute for Biomedical Studies, Integrative Genomics and Bioinformatics Core, La Jolla, CA.
Benji PortilloSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Marcos Garcia TenecheSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Rouven ArnoldSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Adarsh RajeshSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Jessica ProulxSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Shanshan YinSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Aaron HavasSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Charlene MicianoDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA.
Qian YangDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA.
Elizabeth SmootDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA.
Sainath MamdeDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA.
Andrew DavisSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.
Kevin YipSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.ORCID 0000-0001-5516-9944
Allen WangDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA.
Bing RenCenter for Epigenomics, University of California San Diego, La Jolla, CA, USA.
April WilliamsSalk Institute for Biomedical Studies, Integrative Genomics and Bioinformatics Core, La Jolla, CA.
Susan KaechNOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, California, USA.
Peter D AdamsSanford Burnham Prebys Medical Discovery Institute, Cancer Genome and Epigenetics Program, La Jolla, CA.

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
STRUCTURAL BASIS FOR EPIGENETICS IN AGING AND LONGEVITYP01AG031862 · NIA · WISTAR INSTITUTE · PI ZHANG, RUGANG · 2008 to 2022
$28.3M
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapyP01AG073084 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PETER D. ADAMS, GERALD SHADEL · 2021 to 2026
$13.6M
Spatial Mapping Senescent Cells Across the Mouse Lifespan by Multiplex Transcriptomics and EpigenomicsU54AG079758 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PETER D. ADAMS · 2022 to 2026
$12.1M
Beckman Coulter Biomek i7 Hybrid automated workstationS10OD036254 · OD · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HUANG, CHUN-TENG · 2024 to 2024
$594k
Cytek Aurora Full Spectrum Flow CytometerS10OD032325 · OD · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ALTMAN, YOAV · 2022 to 2022
$468k
NCI NIH HHS P30 CA030199NIA NIH HHS P01 AG031862NIA NIH HHS P01 AG073084NIA NIH HHS U54 AG079758NIH HHS S10 OD032325NIH HHS S10 OD036254
6 · The paper itself

Abstract

Liver cancer incidences increase dramatically beyond 55 years of age, suggesting that age-associated changes contribute critically to tumor initiation. However, the mechanisms linking liver aging and cancer initiation are not well defined. This study investigates the role of CD44, a marker of liver tumor-initiating cells (TIC), in age-associated liver pathophysiology. Aged livers showed accumulation of CD44-expressing hepatocytes exhibiting enrichment of immune modulatory genes and activation of the immunosuppressive IL6/JAK/STAT3 pathway. Indeed, in adoptive transfer assays, antigen-exposed CD8+ T cells mounted a lower IFN-γ response in aged livers than in young livers, indicating an immunosuppressive aged milieu. Concordantly, spatial analyses showed that the proximal neighbourhoods of

Identifiers

PMID41509421
PMCPMC12776055

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.